CTAD 2024 Conference Highlights

CTAD, the only conference that brings together the world’s leading AD/ADRD clinical trialists from academia, industry, and not-for-profit organizations with a focus on Alzheimer’s Disease therapeutic trials, took place in Madrid earlier this month, with ATRI leadership proudly participating.

The annual event boasted a series of panels and keynote speakers who showcased the latest developments in Alzheimer's research and prevention.  ATRI leadership, including Paul Aisen, Rema Raman, Doris Molina Henry, Robert Rissman, Oliver Langford, Michael Donohue, Gustavo Jimenez-Maggiora, and Michael Rafii, provided insights into some of the work being done by ATRI and their collaborators.

Michael Rafii, Medical Director of ATRI, was featured in the new therapies and clinical trials session of the conference.  Presenting at the CTAD Task Force meeting, Dr. Raffi delved into ACTC-DS-affiliated clinical trials specifically designed for people with Down syndrome.  The presentation highlighted the ABATE trial, which is testing an anti-amyloid vaccine, the HERO trial, which is targeting the APP gene, and the ALADDIN trial, which will evaluate the FDA-approved treatment donanemab in individuals with Down syndrome.

Reflecting on the conference, Dr. Rafii noted, "I appreciated the discussions as well as the opportunity to connect with colleagues from around the world. Highlights for me included seeing data on the impressive accuracy of blood tests, the first evidence of an anti-tau therapy that reduces tau tangles in the brain, and findings on modified dosing of donanemab that helped reduce side effects."

CTAD24 concluded with resounding vigor, leaving participants committed to continuing the vital partnership and collaboration among the international Alzheimer's research community that fosters advancements in awareness, research, and therapeutic trials.

Looking ahead, CTAD 2025 is scheduled to take place in ATRI's backyard in San Diego, California from December 1-4.  ATRI looks forward to having a presence and voice at the event where once again, global leaders  can gather to share groundbreaking updates and achievements in their field.

Below are select photos from this year's conference.

Screenshot 2024-11-05 at 11.01.28 AMDr. Reisa Sperling, Professor of Neurology and co-Principal Investigator of the Harvard Aging Brain Study

Screenshot 2024-11-05 at 11.00.40 AMDr. Scott Turner, Program Director, The Memory Disorders Program at Georgetown University & Dr. Rema Raman, Director of Biostatistics at the USC Alzheimer’s Therapeutic Research Institute

Screenshot 2024-11-05 at 11.02.36 AMCTAD Opening Ceremony Panel (from left to right): Pascual Sánchez-Juan, Jacques Touchon, Leocadio Rodríguez Mañas, Merce Boada, Bruno Vellas, Paul Aisen, Reisa Sperling, and Mike Weiner

Screenshot 2024-11-05 at 11.03.12 AM

Dr. Anton Porsteinsson, Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program, Irina Skylar-Scott, IMPACT-AD Alumni-Scholar, Bernadette Fausto, IMPACT-AD Alumni-Scholar, Davide Angioni, CTAD Emerging Leader Presenter, Michael Rafii, Medical Director of ATRI, and Haruaki Horie, CTAD Emerging Leader Presenter

 

9860 Mesa Rim Road,
San Diego, CA 92121
ATRIinfo@usc.edu
Phone: (858) 964-4644
Fax: (858) 622-1904

Sign up for our Newsletter

Stay up to date with the latest news in Alzheimer’s theraputics.